Core Laboratories Inc.
CLB
$12.62
$0.302.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 31.40M | 26.20M | 23.71M | 37.52M | 36.68M |
| Total Depreciation and Amortization | 14.95M | 15.16M | 15.42M | 15.58M | 15.78M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.16M | 7.42M | 8.73M | -566.00K | 1.10M |
| Change in Net Operating Assets | 7.88M | 6.43M | -5.96M | -19.05M | -28.77M |
| Cash from Operations | 56.39M | 55.20M | 41.89M | 33.49M | 24.79M |
| Capital Expenditure | -13.03M | -11.38M | -12.12M | -11.42M | -10.58M |
| Sale of Property, Plant, and Equipment | 1.74M | 999.00K | 933.00K | 998.00K | 485.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.90M | 5.10M | 3.00M | 4.15M | 3.44M |
| Cash from Investing | -6.39M | -5.28M | -8.18M | -6.27M | -6.65M |
| Total Debt Issued | 44.00M | 50.00M | 113.00M | 192.00M | 202.00M |
| Total Debt Repaid | -82.00M | -89.00M | -148.00M | -212.00M | -211.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5.31M | -2.19M | -2.21M | -2.25M | -2.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.88M | -1.87M | -1.87M | -1.87M | -1.87M |
| Other Financing Activities | -775.00K | -2.00M | -3.14M | -4.47M | -5.38M |
| Cash from Financing | -45.96M | -45.06M | -42.22M | -28.59M | -18.45M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.04M | 4.86M | -8.51M | -1.37M | -308.00K |